The EATG aims to abide by the UNAIDS terminology guidelines to the greatest extent possible. According to the guidelines ‘people should never be referred to as an abbreviation, such as PLHIV, since this is dehumanizing. Instead, the name or identity of the group should be written out in full. Abbreviations for population groups can, however, be used in charts or graphs where brevity is required’. As many abbreviations referring to people are widely used, we include them in this list.

 

3TClamivudine
ABCabacavir
AIDSacquired immunodeficiency syndrome
ARTantiretroviral therapy
ARVantiretroviral (drug)
ATVatazanavir
ATV/ratazanavir/ritonavir
AVACAIDS Vaccine Advocacy Coalition
AZTzidovudine (also known as ZDV)
BMIbody mass index
bNAbsbroadly neutralizing HIV-1 antibodies
CD4T–lymphocyte cell bearing CD4 receptor
CDCUnited States Centers for Disease Control and Prevention
CHIPCentre of Excellence for Health, Immunity and Infections
CNScentral nervous system
CoPEcontinuous patient education
d4Tstavudine
DALYsdeath- and disability-adjusted life-years
DBSdried blood spot
ddIdidanosine
DNAdeoxyribonucleic acid
DRVdarunavir
DRV/rdarunavir/ritonavir
EU CSFEuropean Union Civil Society Forum
ECEuropean Commission
ECABEuropean Community Advisory Board
ECDCEuropean Centre for Disease Prevention and Control
EFGCPEuropean Forum for Good Clinical Practice
EUPATIEuropean Patients’ Academy on Therapeutic Innovation
EFPIAEuropean Federation of Pharmaceutical Industries and Associations
EFVefavirenz
eGFRestimated glomerular filtration rate
EHVAEuropean HIV Vaccine Alliance
ELISAenzyme-linked immunosorbent assay
EMAEuropean Medicines Agency
EMCDDAEuropean Monitoring Centre for Drugs and Drug Addiction
EPFEuropean Patients’ Forum
EPHAEuropean Public Health Alliance
ESF+European Social Fund Plus
ESTICOMEuropean Surveys and Trainings to Improve MSM Community Health
ETVetravirine
ETWEuropean Testing Week
EUPATIEuropean Patients’ Academy on Therapeutic Innovation
FPVfosamprenavir
FPV/rfosamprenavir/ritonavir
FTCemtricitabine
GAgeneral assembly
GNP+Global Network of People Living with HIV
HBsAghepatitis B surface antigen
HBVhepatitis B virus
HCVhepatitis C virus
HIVhuman immunodeficiency virus
HPTNHIV Prevention Trials Network
HSVherpes simplex virus
HTAhealth technology assessment
IDUinjecting drug users
ILGAInternational Lesbian, Gay, Bisexual, Trans and Intersex Association
IMIInnovative Medicines Initiative
INIsintegrase inhibitors
INHisoniazid
IPPFInternational Planned Parenthood Federation
IPTisoniazid preventive therapy
IRISimmune reconstitution inflammatory syndrome
LMICslow- and middle- income countries
LPVlopinavir
LPV/rlopinavir/ritonavir
MDRmultidrug-resistant TB, resistant to at least isoniazid and rifampicin
MSMmen who have sex with men
MTCTmother-to-child transmission (of HIV)
NASHnon-alcoholic steatohepatitis
NFVnelfinavir
NNRTInon-nucleoside reverse-transcriptase inhibitor
NRTInucleoside reverse-transcriptase inhibitor
NVPnevirapine
OSTopioid substitution therapy
PARADIGMPatients Active in Research and Dialogues for an Improved Generation of Medicines
PCP/PJPpneumocystis (jirovecii) pneumonia
PCRpolymerase chain reaction
PEpatient engagement
PIprotease inhibitor
PICUMPlatform for International Cooperation on Undocumented Migrants
PLHIVpeople living with HIV
PMTCTprevention of mother-to-child transmission of HIV
PrEPpre-exposure prophylaxis of HIV
PREMspatient-reported outcome experiences
PROMspatient-reported outcome measures
QoLquality of life
R&Dresearch and development
RALraltegravir
RBVribavirin
RIFrifampicin
RNAribonucleic acid
RTVritonavir
SDGsustainable development goals
SDTsingle-dose tablet
SPCsupplementary protection certificates
TAFtenofovir alafenamide fumarate
TasPtreatment as prevention
TBtuberculosis
TB CABGlobal Tuberculosis Community Advisory Board
TDFtenofovir disoproxil fumarate
UNAIDSJoint United Nations Programme on HIV/AIDS
UNICEFUnited Nations Children’s Fund
UNODCUnited Nations Office on Drugs and Crime
WHOWorld Health Organization

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.